<DOC>
	<DOCNO>NCT01239017</DOCNO>
	<brief_summary>This double-blind , prospective , randomized study patient randomize 1 5 treatment arm ( 4 active 1 placebo ) . Each patient receive one SC injection REGN475 placebo 1 IV infusion either REGN475 placebo , day 1 ( baseline ) In order preserve blind , patient receive REGN475 SC also receive placebo IV , patient receive REGN475 IV also receive placebo SC .</brief_summary>
	<brief_title>A Study Safety Efficacy Subcutaneously Administered REGN475 Patients With Osteoarthritis Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>1 . Diagnosis OA knee accord American College Rheumatology ( ACR ) criterion , experience moderate severe pain index knee least 3 month prior screen visit . 2 . KellgrenLawrence grade 23 radiographic severity index knee within 6 month prior Screening . 1 . Significant concomitant illness include , limited , cardiac , renal , neurological , endocrinological , metabolic lymphatic disease would adversely affect patient 's participation study . 2 . Patients joint replacement affect knee . 3 . Intraarticular injection corticosteroid hyaluronic acid affect knee within 3 month prior screen visit . 4 . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>